PITTSBURGH--(BUSINESS WIRE)--Helomics (formerly Precision Therapeutics), a privately held comprehensive personalized healthcare company that develops innovative next generation diagnostics for the oncology field, announced today that it will be recognized as a recipient of the 2014 Pittsburgh Smart 50 Awards, presented by Chase and Smart Business. President and CEO Neil Campbell will accept the award on behalf of Helomics at the awards ceremony on Nov. 19 at the Marriott Pittsburgh City Center.
The Pittsburgh Smart 50 awards recognize the top executives of the smartest 50 companies in the region for their ability to effectively build and lead organizations with a strong commitment to innovation, community impact and leadership. The inaugural class of Smart 50 honorees represents a diverse set of businesses and industries, ranging from manufacturing to finance to not-for-profits. These businesses have contributed to the region’s growth, strength and success.
Campbell was recently appointed as President and CEO of Helomics, and over the past three decades he has helped commercialize more than 275 life sciences products and services. Campbell also serves as a Director on Helomics’ new Board of Directors, comprised of five additional prominent industry veterans. Campbell and the senior management team bring strategic vision to Helomics, aiming to develop more comprehensive services to Helomics’ portfolio, intended to help physicians individualize treatment options for their patients.
“We’re honored by this award as it represents the hard work our team at Helomics is doing and the dedication our company has to making a difference in the lives of people with cancer,” Campbell said. “The city of Pittsburgh is a great source of pride for Helomics as the community here provides us with unique opportunities for growth, innovation, research and partnership. I truly believe Pittsburgh is one of the best kept secrets in the biotech and life science industry in the United States.”
About Helomics™ Corporation
Helomics is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by utilizing a proprietary set of laboratory platforms and our product science as a service commercialization model to allow physicians to characterize malignant tumors. Helomics’ novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.